Frequency and significance of granulomas in a cohort of incident cases of Crohn’s disease


Background and aims: Epithelioid granulomas is one of the best histological criterion for distinguishing Crohn’s disease (CD) from other inflammatory bowel diseases. Few data are available on the time of occurrence of epithelioid granulomas, and the value of epithelioid granulomas in predicting outcome has been determined only in cohorts of prevalent CD cases. Our objective was to evaluate epithelioid granuloma occurrence in incident CD cases and to examine the associations between epithelioid granulomas and outcome.

Patients and methods: We reviewed the histological reports of endoscopic and surgical specimens in a cohort of 188 consecutive incident CD cases seen in 1994 and 1995, and recorded the occurrence of epithelioid granulomas, isolated giant cells, and microgranulomas. Kaplan-Meier curves were plotted for time from CD diagnosis to immunosuppressive treatment or surgery, and associations between epithelioid granulomas and outcome were evaluated in a multivariate analysis. Follow up was at least five years.

Results: Granulomas were found in 69 (37%) patients, including 48 (25%) at presentation. Median time from CD diagnosis to epithelioid granuloma detection was 0.16 (0–63) months overall, and 9.59 (0.1–63) months in 23 patients who became epithelioid granuloma positive during follow up. Isolated giant cells were found in 6% of patients and microgranulomas in 12%. Epithelioid granuloma detection increased with the number of endoscopic sampling procedures; sampling site had no influence. By multivariate analysis, epithelioid granulomas were associated with surgical resection but not immunosuppressive therapy.

Conclusions: Epithelioid granulomas may separate CD into two pathological subsets and may indicate aggressive disease.

Crohn's disease (CD) and ulcerative colitis, although sensitivities of less than 75% have been reported for this distinction. Histological guidelines for diagnosing inflammatory bowel disease (IBD) and distinguishing CD from ulcerative colitis have been developed. Several classification schemes list criteria for a definite, probable, or possible diagnosis, with presence of epithelioid granulomas indicating definite CD. Although interobserver agreement for epithelioid granulomas is good, occurrence rates vary across series of CD patients, probably as a result of differences in patient populations or in biopsy technique (for example, serial sectioning versus step sectioning). Among patients with onset of IBD within the last year, only 12% had detectable epithelioid granulomas. Nevertheless, a study specifically designed to compare histological findings in biopsy specimens from patients with recent onset or chronic IBD found no difference in the rate of occurrence of epithelioid granulomas. A trend towards a higher rate of epithelioid granulomas has been found in paediatric CD patients but only cohort studies of prevalent CD cases included both children and adults. Epithelioid granulomas predicted CD outcome in several studies although they were unhelpful in assessing disease activity. Most of these previous studies examined surgical specimens or cross sectional collections of histological samples and used recurrence after the first resection procedure as the primary outcome variable. Moreover, outcomes were evaluated in prevalent cases of CD, and the presence of epithelioid granulomas was determined only in a limited number of tissue samples, usually surgical specimens as opposed to all biopsy and surgical specimens obtained since CD onset.

To evaluate the rate of occurrence and potential prognostic significance of epithelioid granulomas in CD, we recorded the presence of epithelioid granulomas over a five year period in a large cohort of patients with incident CD, using all available specimens, and we assessed correlations between the presence of epithelioid granulomas and clinical outcome.

PATIENTS AND METHODS

Patients

A population based inception cohort established for an earlier study was used. All patients given a diagnosis of IBD during a two year period (1994–1995) were identified prospectively by gastroenterologists who maintain a registry of IBD in Brittany (ABERMAD, France). These gastroenterologists use a standardised case ascertainment procedure and meet annually with pathologists to examine diagnostic guidelines and to update their practice.

Among patients in the registry, those with CD were identified based on well established clinical, endoscopic, radiological, and histological criteria. During the study period, 214 patients with CD were entered into the registry. The following data were recorded for each patient: age, sex, age at diagnosis, initial and cumulative disease locations.

Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; OR, odds ratio
date of upper or colonic endoscopy, date of and reason for each operative procedure, date of the first course of each treatment (including salicylates, glucocorticoids, or immunosuppressive drugs such as azathioprine, methotrexate, and infliximab), occurrence of extraintestinal manifestations, and duration of follow up from CD diagnosis to final evaluation. Surgery was defined as any operation for CD but procedures were classified into several categories, and those involving small or large bowel resection were identified. The occurrence of medical events at any time during follow up was recorded. The final evaluation was performed during the second half of 2001 and consisted of obtaining data from the gastroenterologist and general practitioner, by mail and, if needed, by telephone call. These data were available for 188 (88%) patients who form the basis for the present study.

All histological slides from endoscopic and surgical specimens were reviewed by four IBD experts for the presence of epithelioid granulomas and other histopathological features previously identified as relevant—namely, giant cells and microgranulomas4–7—defined according to our previous report4; an epithelioid granulomas is a collection of at least five epithelioid cells with or without accompanying giant cells, and without caseating necrosis or foreign bodies. A microgranuloma is an aggregate of histiocytes and lymphocytes; giant cells are absent. Giant cells contain multiple nuclei and homogenous, fine, powdery cytoplasm without foreign bodies. Correlations were sought between histological findings, including the presence of epithelioid granulomas, and two main outcome variables—need for immunosuppressants and need for surgical resection.

Of 2600 histological specimens from 414 endoscopic biopsy or surgical procedures, 2443 were obtained from 370 sampling procedures by endoscopy and 157 from 44 surgical procedures. Because of the variation in affected bowel sites, the heterogeneous pattern of endoscopic biopsies, and absence of routine upper gastrointestinal endoscopy, we classified the histological specimens by site sampled, as follows: oesophagus, stomach, and duodenum, with 290 biopsies from 66 procedures; ileum 453 biopsies from 125 procedures; colon, 1470 biopsies from 297 procedures; and rectum, 230 biopsies from 62 procedures. This resulted in a mean of 2.2 (SD 1.2) sampling endoscopic procedures (median 2 (range 1–6)) and 14.3 (11.8) endoscopic biopsies (median 10 (range 2–74)) per patient. The 44 surgical procedures for CD were performed in 41 patients, 28 of them for intestinal or colonic resection and 14 for anorectal surgery (one patient had both types of surgery). Histological features analysed were defined as previously described.4,5,7 In an earlier study,4 we found that epithelioid granulomas, microgranulomas, and giant cells were the best predictors of CD and that, in a logistic regression model with a stepwise ascending procedure, these three histological features identified a distinctive histological pattern present in a subset of CD patients. Therefore, we focused the present study on these three histological findings.

### Statistical analysis

Results are expressed as mean (SD) or median (range) according to the data distribution for each variable. Differences between patients with and without epithelioid granulomas were compared using the independent sample t test or Wilcoxon’s test for normally and non-normally distributed variables, respectively. χ² tests or Fisher’s exact test was used for categorical variables. A p value <0.05 was considered statistically significant.

Associations linking each variable to the presence of epithelioid granulomas were evaluated by determining the odds ratios (ORs) with their 95% confidence intervals (95% CI) calculated from logistic regression coefficients and their standard errors. Times from CD diagnosis to immunosuppressive treatment or surgery were estimated using the Kaplan-Meier technique and compared using the log rank test. A Cox proportional hazards model allowed simultaneous adjustment of each variable in the model for all other variables (forced selection model). Variables with p values <0.1 were included in the Cox model. The SPSS package (version 11.0, SPSS France, 75002 Paris) was used for data management and data analysis.

### RESULTS

#### Rate of occurrence of epithelioid granulomas

Table 1 reports the main patient characteristics. At inclusion, 46 (25%) patients had epithelioid granulomas; 13 (7%) had giant cells, which were isolated in six patients, and nine (5%) had microgranulomas, which were isolated in four patients. At the last follow up, 69 (37%) patients had epithelioid granulomas, 22 (12%) had giant cells (without granulomas in 11 patients), and 22 (12%) had microgranulomas (without granulomas in 10 patients); among these 69 patients, 48 patients had isolated granulomas without giant cells or microgranulomas. Of the 69 patients with epithelioid granulomas, 49 were detected in endoscopic biopsies only, 14 in surgical specimens only, and six in both specimen types; in these six patients, granulomas were observed for the first time on endoscopic biopsies and surgical samples in four and two cases, respectively. Therefore, granulomas were observed for the first time on endoscopic biopsies and on surgical samples in 53 and 16 patients, respectively.

Epithelioid granulomas were found in 25/98 (26%) patients investigated by colonoscopy only, in 19/54 (35%) patients investigated by both upper gastrointestinal endoscopy and colonoscopy, and in 25/35 (71%) surgical specimens (one patient was investigated only by upper gastrointestinal endoscopy and small bowel contrast). Epithelioid granulomas were found in 6%, 16%, 14%, 25%, and 16% of biopsies from the upper gastrointestinal tract, ileum, right colon, left colon, and rectum, respectively, and in 8%, 21%, 16%, 27%, and 23% of patients with biopsies from these sites, respectively. The 69 patients with epithelioid granulomas underwent 1–6 procedures for biopsies during follow up; the proportions of patients with epithelioid granulomas were 35%, 40%, 45%, 44%, 63%, and 25% in the subgroups defined by the number of procedures, from 1 to 6, respectively.

Mean time to granuloma development was 0.16 months (range 0–63) in the 69 patients overall and 9.59 months (range 0.1–63) in the 23 patients whose granulomas developed after the diagnosis of CD. In the 69 patients with granuloma, 163 sampling procedures were done in total (including endoscopic biopsies and surgery), of which 95 (58%) showed granulomas. Among these 69 patients, the

---

**Table 1 Characteristics of the 188 patients at inclusion**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (SD)</th>
<th>Median (range)</th>
<th>Sex (F/M)</th>
<th>Time from symptom onset to diagnosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>36.4 (20.2)</td>
<td>29 (6–65)</td>
<td>98/90</td>
<td>6.9 (10.5)</td>
</tr>
<tr>
<td>Duration (months)</td>
<td>2 (0.1–72.0)</td>
<td>2.6 (0.1–84.0)</td>
<td>88%</td>
<td>6.7 (9–92.8)</td>
</tr>
</tbody>
</table>

*Delay between onset and last histological sample either by endoscopic or surgical procedure.*
likelihood that granulomas would be found by endoscopic or surgical procedures performed after a granuloma positive procedure was 44% (23/52). Of the 69 patients, 52 underwent at least two sampling procedures; of these 52 patients, 13 (13/52, 25%) were found to have granulomas after two procedures; three and four of 29 patients who had at least three procedures had granulomas after two and three procedures, respectively; four, three, and two of 15 patients who had at least four procedures had granulomas after two, three, or four procedures, respectively; and two of seven patients who had five procedures had granulomas after two, three, four, or five procedures. Of the 69 patients with granulomas at presentation, among the 69 patients with granulomas, five had giant cell detection during follow up; among these five patients, three had giant cells detected by the biopsy procedure that detected granulomas; in one patient the giant cells were found after a later biopsy procedure and in another patient after a biopsy procedure performed 12 months earlier. Microgranulomas were found in 22 (12%) patients at the last follow up, of whom five also had granulomas, and in 22 (12%) patients at the last follow up, of whom 12 also had granulomas.

Twenty two patients had giant cells (without granulomas in 50% of cases). Giant cells were found at diagnosis in 13 patients (5/46 and 8/142 patients with and without granulomas, respectively) and during follow up in nine patients (5/69 and 4/119 with and without granulomas, respectively). Median time to giant cell detection was 0.18 months (range 0–67) overall, 0.16 (0–67) months in 10 patients with granulomas (10/69), and 0.19 (0–51) months in 12 patients without granulomas (12/119). Of nine patients with giant cell detection during follow up, four (4/119) had no granulomas at any time and had a median time to giant cell detection of 34 months (range 2–51), and four (4/23) had granuloma development during follow up and a median time to giant cell detection of 48 months (range 0.1–65).

Finally, isolated granulomas, giant cells, and microgranulomas were found in 22 (12%) patients at the last follow up, of whom 12 also had granulomas.

Table 2  Number of biopsy specimens, number of endoscopic or surgical sampling procedures, histological follow up duration, and time to granuloma development in patients with and without epithelioid granulomas

<table>
<thead>
<tr>
<th></th>
<th>No of granulomas at inclusion (n = 46)</th>
<th>Granulomas found during follow up (n = 23)</th>
<th>Granulomas at last follow up (n = 69)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of biopsies*</td>
<td>Mean (SD)</td>
<td>Median (range)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>16.5 (14.4)</td>
<td>13 (2–74)</td>
<td>16.2 (11.7)</td>
</tr>
<tr>
<td>No of sampling procedures</td>
<td>Mean (SD)</td>
<td>Median (range)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>3.2 (1.2)</td>
<td>2.1–6</td>
<td>3.2 (1.2)</td>
</tr>
<tr>
<td>Histological follow up duration (months)</td>
<td>Mean (SD)</td>
<td>Median (range)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>23.6 (27.5)</td>
<td>7.8 (0–76)</td>
<td>33.8 (27.1)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>33.8 (0–84)</td>
<td>14.4 (0–84)</td>
<td>27.0 (27.6)</td>
</tr>
<tr>
<td>Time to granuloma detection (months)</td>
<td>Mean (SD)</td>
<td>Median (range)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>0.19 (0.76)</td>
<td>0.09 (0–3.78)</td>
<td>18.14 (20.26)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>9.59 (0–63)</td>
<td>6.17 (14.34)</td>
<td>16.0 (68.0)</td>
</tr>
</tbody>
</table>

*Total number of endoscopic biopsies or surgical samples per patients whatever the site during all of the follow up period.

Table 3  Comparison of the 69 patients with and 119 patients without granulomas

<table>
<thead>
<tr>
<th>Granulomas (%) (n = 69)</th>
<th>No granulomas (%) (n = 119)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>34.2 (20.6)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>25.8 (5–85)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>38/31</td>
</tr>
<tr>
<td>Follow up duration (months)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>57.8 (27.2)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>67 (0–93)</td>
</tr>
<tr>
<td>Extraintestinal manifestations Initial</td>
<td>9 (20)*</td>
</tr>
<tr>
<td>At last follow up</td>
<td>20 (29)*</td>
</tr>
<tr>
<td>12 patients with CD</td>
<td></td>
</tr>
<tr>
<td>D’Amico Malignant</td>
<td>5 (11)</td>
</tr>
<tr>
<td>No of anoperineal surgery</td>
<td>14 (20)***</td>
</tr>
<tr>
<td>Patients with surgery for CD</td>
<td>25 (36)***</td>
</tr>
<tr>
<td>Patients with surgical bowel resection</td>
<td>18 (28)***</td>
</tr>
</tbody>
</table>

CD, Crohn’s disease.

*p<0.05; **p<0.001.

Figure 1  Time to immunosuppressive treatment in 69 patients with and 119 without epithelioid granulomas (EG).
218 Heresbach, Alexandre, Branger, et al

www.gutjnl.com

2–56) (p = 0.15).

Compared with the 119 patients without granulomas, the 69 patients with granulomas were more likely to have anoperineal involvement at presentation or at the last follow up, systemic glucocorticoid therapy, immunosuppressive therapy, and admissions for CD flares (table 3). Bowel resection was performed in a significantly larger proportion of patients with than without granulomas (19/69 (27.5%) v 10/119 (8.4%), respectively; p < 0.001); in these two groups, colonic resection was performed in five and three patients, small bowel resection in six patients and one patient, and ileocolonic resection in seven and six patients, respectively. In addition, anoperineal surgery was performed in 8/69 (11.6%) patients with granulomas (14 procedures) and in 6/119 (5.0%) patients without granuloma (seven procedures). Anoperineal involvement at the last follow up (17/53 v 3/16), systemic glucocorticoid therapy (39/53 v 9/16), and immunosuppressive therapy (13/53 v 4/16) were not different in 53 and 16 patients with granulomas observed for the first time in endoscopic biopsies or surgical samples, respectively, and use of immunosuppressants occurred no more often or sooner during follow up in these 53 and 16 patients (log rank test, NS).

A trend towards earlier use of immunosuppressants (azathioprine and/or methotrexate and/or infliximab) was noted in the 69 patients with granulomas compared with the 119 patients without granulomas (log rank test, p < 0.06) (fig 1). Both bowel resection (fig 2B) and any abdominal or proctological surgery for CD (fig 2A) occurred significantly more often and earlier during follow up in the 69 patients with granulomas than in the 119 patients without granulomas. Bowel resection and/or immunosuppressive therapy occurred significantly more often and earlier in the 69 patients with granulomas than in the 119 without granuloma (log rank test, p < 0.001) (fig 3).

Figure 2 Time to first (A) surgery for Crohn’s disease or (B) small bowel or colon resection in 69 patients with and 119 without epithelioid granulomas (EG).

Implications of epithelioid granulomas

The 69 patients with granulomas had a significantly larger median number of biopsies (14 (range 2–74)) than the 119 patients without granulomas at the last follow-up (9 (range 2–56)) (p < 0.01) (table 2). In the 23 patients in whom granulomas were detected during follow up, the median number of biopsies was 16 (range 4–41) compared with 9 (range 2–56) in the 119 patients without granulomas (table 2). The median number of sampling procedures (endoscopic biopsies or surgery) was 2 (range 1–6) in the 69 patients with granulomas and 2 (1–6) in the 119 patients without granulomas (p < 0.005). In the 23 patients with granuloma detection during follow up, the median number of sampling procedures was 3 (range 2–5) compared with 2 (1–6) in the 119 patients without granulomas (p < 0.0001).

Median histological follow up duration (that is, time between inclusion and last histological samples) was significantly longer in the 69 patients with granulomas (14.4 months (range 0–84)) than in the 119 patients without granulomas (3.2 months (range 0–73); p < 0.009) (table 2). Nevertheless, the median histological follow up duration in the 119 patients without granulomas was significantly longer than the median time to first granuloma detection in the 69 patients with granulomas (3.18 months (0–73) v 0.16 months (0–68), respectively; p < 0.0001) and was similar to the median time to granuloma detection in the 23 patients in whom granulomas were absent at presentation but were detected during follow up (3.18 months (0–73) v 9.59 months (0–63); p = 0.15).

whereas 17 patients had either giant cells or microgranulomas without granulomas at inclusion or during follow up. Duration of follow up of these 17 patients was 59 (23) months compared with 58 (27) (NS) and 61 (27) (NS) months in the 69 and 48 patients with granulomas or isolated granulomas.

Figure 3 Time to immunosuppressive drug therapy or to bowel resection in 69 patients with and 119 patients without epithelioid granulomas (EG).
We also compared the prognosis of patients with granulomas observed for the first time on endoscopic biopsies (n = 53) with patients without granulomas at inclusion or during follow up (n = 119). Anoperineal involvement (17/53 v 13/119; p < 0.0005), glucocorticoid therapy (39/53 v 47/119; p < 0.0001), and immunosuppressant use (13/53 v 16/119; p < 0.05) were always significantly more frequent in 53 patients with granulomas on endoscopic biopsies than in patients without granulomas. Moreover, immunosuppressive treatment (log rank test, p < 0.06) and time to immunosuppressive drug therapy or to bowel resection (log rank test, p < 0.05) tended to occur more often and earlier in these 53 compared with the 119 patients without granulomas. Finally, to definitively exclude dependence of granuloma diagnosis on surgical sampling, we analysed the predictive value of granulomas for immunosuppressive therapy in patients who had not undergone surgery; in these 147 cases, 44 and 103 were patients with and without granulomas, respectively. Using the Kaplan-Meier technique, the rate of immunosuppressive therapy was higher in patients with granulomas than in the 119 patients without granulomas (log rank test, p < 0.03) (fig 4).

In the multivariate model (table 4) with epithelioid granulomas as the dependent variable, the following covariates were introduced: follow up duration, number of endoscopic or surgical procedures, number of biopsies during follow up, presence of anal or perineal disease, and age at diagnosis. Presence of epithelioid granulomas (p < 0.005) as well as age at diagnosis (p < 0.05) independently predicted surgery for CD (table 4) but epithelioid granulomas alone predicted surgical resection (p < 0.03). Only age at diagnosis was an independent predictor of immunosuppressive treatment (p < 0.001).

**DISCUSSION**

In this study, we found epithelioid granulomas in 25% of CD patients at presentation and in 37% cumulatively by the end of the follow up period. Both endoscopic and surgical histological reports were reviewed by IBD experts, suggesting that the high rate of epithelioid granulomas in our population cannot be ascribed to overdiagnosis resulting from lack of experience with the histological features of epithelioid granulomas in CD. The serial sectioning method,44–45 has been reported to increase the granuloma detection rate by 50% (nine v six patients). However, comparisons of the serial and step sectioning methods in CD were performed in small groups of patients, they failed to specify the timing of sampling relative to the clinical course of CD (time from CD diagnosis to the biopsy showing granulomas and age at CD onset), and took only rectal biopsies into account.14–42

Although the exact number of slides was not recorded in the present study, all histological samples were processed according to the serial sectioning method. Therefore, 20–30 slides of each paraffin block were examined, and this rule was adopted during the ABERMAD annual meeting and medical education from our first study on this topic.12

For our study, we used a population based IBD registry to avoid patient selection on criteria likely to bias the granuloma occurrence rate. In addition, we reviewed both surgical and endoscopic specimens, as granuloma occurrence rates in earlier studies varied widely across these two categories (from 37% to 82% in surgical specimens19–30 33 and from 14% to 56% in endoscopic biopsies).4–7,13,14,16–18,31–34,42–45, 46

When both surgical specimens and endoscopic biopsies were examined, the granuloma occurrence rate ranged from 26% to 73%.13 Interestingly, in surgical studies, the highest rate (82%) was found in a paediatric cohort17 and the lowest (22%) in patients with CD onset after 50 years of age.20 A negative correlation has been reported between patient age at study inclusion and granuloma rate in several surgical specimen studies17–20 and one endoscopic biopsy study,25 although this last finding was not confirmed in subsequent work by the same group.18 Moreover, a single study, which examined surgical specimens,20 found that CD onset occurred at a younger age in patients with epithelioid granulomas. Whether the higher granuloma rate reported in younger CD patients is attributable to earlier CD onset in patients with granulomas, to a shorter time from CD onset to sampling, or to both factors remains unclear. In our study, age at CD onset

**Table 4** Multivariate analysis of risk (relative risk (RR) and 95% confidence interval (CI)) of immunosuppressive treatment or surgery for Crohn’s disease (CD)

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Immunosuppressive treatment (RR (95% CI))</th>
<th>Surgery for CD (RR (95% CI))</th>
<th>Surgical resection (RR (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of follow up</td>
<td>1.0 (0.98–1.02)</td>
<td>1.0 (0.59–1.02)</td>
<td>1.00 (0.99–1.03)</td>
</tr>
<tr>
<td>No of endoscopic or surgical procedures</td>
<td>1.15 (0.80–1.66)</td>
<td>2.09 (1.57–2.79)****</td>
<td>2.46 (1.73–3.50)****</td>
</tr>
<tr>
<td>No of biopsies†</td>
<td>0.99 (0.57–1.03)</td>
<td>0.93 (0.89–0.97)***</td>
<td>0.94 (0.91–0.98)***</td>
</tr>
<tr>
<td>Anal or perineal CD</td>
<td>0.98 (0.43–2.19)</td>
<td>0.46 (0.21–1.01)</td>
<td>1.33 (0.49–3.63)</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>0.95 (0.92–0.98)***</td>
<td>0.98 (0.96–0.99)***</td>
<td>0.99 (0.97–1.01)</td>
</tr>
<tr>
<td>Epithelioid granuloma</td>
<td>1.45 (0.68–3.13)</td>
<td>3.33 (1.41–7.90)***</td>
<td>3.23 (1.13–9.26)*</td>
</tr>
</tbody>
</table>

*p < 0.03, **p < 0.04, ***p < 0.001, ****p < 0.006, *****p < 0.0001.

†Total number of endoscopic biopsies or surgical samples per patients whatever the site during all of the follow up period.
was similar in patients with and without granulomas, suggesting selection bias as the explanation for the age-granuloma correlation found in earlier studies; nevertheless, we included age at CD onset among the covariates in our multivariate model.

Our results are in accordance with granuloma rates of 32%, 45%, and 35% in incident cases from epidemiological registries. Few studies have examined histological features or granuloma rates according to time since IBD onset. In one study, granulomas were detected in 5 of 11 (45%) and 3 of 4 (75%) CD patients with follow up shorter and longer than three months since CD onset. Our data suggest that a diagnosis of definite CD may be made only after one year of histological follow up as the median time to granuloma detection was 0.16 months in our 69 patients with granulomas at any time and 9.59 months in the 23 patients with granulomas detected during follow up but not at presentation.

Influence of the sampling site on granuloma occurrence rate would be expected. However, no marked difference was found between the bowel wall (37–78%) and the lymph nodes (20–42%), although granuloma density increased from the ileum to the anus. Moreover, the granuloma rate was not influenced by the site of CD lesions: no noticeable differences in granuloma rates were found across bowel sites of CD involvement. In surgical cohorts, granulomas were found in 46–57% of ileal specimens and in 20–70% of colonic specimens. Granuloma rates in endoscopic cohorts were 17–30% in ileocolonic CD and 13–16% in colonic CD. Among the patients in our study who had biopsies taken from the upper gastrointestinal tract, these showed granulomas in 8% of cases, a proportion in accordance with the 7–50% range in previous studies. Despite the median number of biopsies being larger in the 69 patients with granulomas than in the 119 patients without granulomas, the number of biopsies in the 23 patients with granulomas only detected during follow up was not different from those in the 46 patients with granulomas at inclusion. Moreover, the median number of biopsies in these 119 and 23 patients was above five (nine and 16, respectively). No further increase in the granuloma rate was noted when the number of biopsies increased above five or the number of endoscopic sampling procedures increased above three.

Few studies have reported the proportions of CD patients with isolated giant cells. In our study, the proportion of patients with giant cells increased from 7% to 12% between presentation and the last follow up, and in half of these patients giant cells were isolated, yielding a 6% rate at the last follow up. In a retrospective study of prevalent IBD, well defined epithelioid granulomas or isolated giant cells were strongly associated with a diagnosis of CD when found at a distance from the crypts; among 19 patients with CD confirmed by histological and clinical findings, 10 had epithelioid granulomas and four had giant cells, which were isolated in three (3/19, 16%). The interpretation of crypt associated epithelioid granulomas has not been agreed. In one study, 10 of 14 patients with crypt associated granulomas had CD. Nevertheless, the prevailing opinion is that free standing epithelioid granulomas and giant cells characterise CD whereas the same features associated with crypts indicate granulomatous cryptitis, which is presumably a foreign body reaction to mucus extrusion after crypt rupture. Granulomatous cryptitis was described in six of 23 patients with diverticular disease associated chronic colitis and in 25 of 29 specimens with sigmoid diverticulitis; however, crypt associated granulomas and granulomatous cryptitis were associated with true granulomas throughout the wall and serosal fat, a clear difference from foreign body reactions to facetal material, suggesting that diverticular disease and CD may be associated.

Identification of microgranulomas relies only on morphological analysis. In contradiction with the initial hypothesis put forward about microgranulomas, there is no convincing evidence that these lesions develop immediately before epithelioid granuloma formation. Microgranulomas are uncommon in acute onset CD (10%). Moreover, microgranulomas have been found in only 12% to 24% of CD patients, and have been reported in other inflammatory diseases, including ulcerative colitis, with a rate of 5–7% and in infectious colitis. Our data confirm the low rate of microgranulomas in CD patients and the absence of a marked increase in this rate between presentation (5%) and the last follow up (12%).

Clinical features and outcome in CD patients with and without epithelioid granulomas have received little attention. Earlier CD onset was associated with more frequent CD flares, a positive family history, positive tests for anti-Saccharomyces cerevisiae antibodies, presence of HLA DR7, extensive jejunal and ileal involvement with CD, upper gastrointestinal involvement, and a need for at least one surgical procedure. Presence of epithelioid granulomas in CD patients was strongly associated with a higher rate of postoperative recurrence (that is, with a need for two surgical procedures). Among studies that found no correlation between postoperative recurrence and prior presence of epithelioid granulomas, most based the diagnosis of recurrence on clinical criteria, and only two studies obtained confirmation of the diagnosis by surgery. In an early paediatric cohort, including 56 CD patients, presence of epithelioid granulomas (33% of patients) was associated with a greater likelihood of ileal involvement, perineal disease, and surgery for CD. A more recent study of 82 prevalent CD cases found no difference between patients with (26%) and without epithelioid granulomas regarding the number of patients with extraintestinal CD manifestations, perineal disease, and/or fistulas; among 82 patients, 42 were followed up for longer than one year, and neither the number nor the severity of CD flares during the period differed between the two groups. Finally, two studies evaluated the significance of histological findings as predictors of CD outcome; one sought to identify histological features distinguishing patients with penetrating or stricturing CD lesions from those without complications and another looked for histological patterns predicting relapse of ulcerative colitis. These two studies tested 34 and 14 features, respectively. Granulomas did not predict complications of CD. Our data from CD patients suggest that epithelioid granulomas may be associated with a more aggressive course and may independently predict surgical treatment. However, granulomas did not predict the use of immunosuppressive therapy which was associated only with early age at CD onset. There is no clear explanation for this last finding. Conceivably, a contributing factor may be differences in practice among gastroenterologists regarding the choice between immunosuppressive drugs and surgery, as presence of granulomas independently predicted immunosuppressive therapy and/or surgical resection in our CD patients (OR 2.25 (95% CI 1.13–4.43)).

In conclusion, this study supports the hypothesis that epithelioid granulomas characterise a patient subset with a more aggressive clinical course but without earlier onset of CD or an increased risk of systemic manifestations. Our data also suggest that epithelioid granulomas may be a valuable predictor of the need for more aggressive management in CD patients. This possibility requires further investigation to provide targeted therapy according to the presence or absence of granulomas in CD.
ACKNOWLEDGEMENTS
We thank all the ABERMAD members who participated in this study. This work was supported by a grant from the French National Society of Gastroenterology (SNFGE 1999) and from Ferring SA.

Authors’ affiliations

Conflict of interest: None declared.

ABERMAD is a non-profit organisation for research on gastrointestinal diseases, affiliated with the Pontchaillou Teaching Hospital, Rennes, France.

REFERENCES
EDITOR’S QUIZ: GI SNAPSHOT

Chronic intermittent vomiting after scoliosis surgery

Clinical presentation
A 12 year old girl presented with an 18 month history of intermittent postprandial vomiting and abdominal distension following scoliosis surgery. Her family history was unremarkable. On examination, her abdomen was slightly distended without tenderness. Bowel sounds were increased. Laboratory values were normal. Upper gastrointestinal study is depicted in fig 1.

Question
What is the diagnosis?
See page 281 for answer
This case is submitted by:

A Hokama, R Tomiyama, K Kishimoto, F Kinjo, A Saito
First Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan

M Matayoshi
Matayoshi Clinic, Okinawa, Japan

Correspondence to: Dr A Hokama, First Department of Internal Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan; hakama-a@med.u-ryukyu.ac.jp
doi: 10.1136/gut.2004.044313

Figure 1 Barium contrast study of the duodenum.
Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease

D Heresbach, J L Alexandre, B Branger, J F Bretagne, E Cruchant, A Dabadie, M Dartois-Hoguin, P M Girardot, H Jouanolle, J Kerneis, J C Le Verger, V Louvain, J Politis, M Richecoeur, M Robaszkiewicz and J A Seyrig

Gut 2005 54: 215-222
doi: 10.1136/gut.2004.041715

Updated information and services can be found at:
http://gut.bmj.com/content/54/2/215

These include:

References
This article cites 65 articles, 15 of which you can access for free at:
http://gut.bmj.com/content/54/2/215#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/